Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

EQS-Adhoc: BB Biotech AG publishes its interim report
EQS-Adhoc: BB Biotech AG publishes its interim report
EQS-Adhoc: BB Biotech AG publishes its interim report
EQS-News: BB Biotech Q2 2025: outperforms Nasdaq Biotech Index; strong USD returns, currency drag in CHF
EQS-News: BB Biotech Q2 2025: outperforms Nasdaq Biotech Index; strong USD returns, currency drag in CHF
EQS-News: BB Biotech Q2 2025: outperforms Nasdaq Biotech Index; strong USD returns, currency drag in CHF
Evolva Holding SA: Update about earn-out from Danstar
Evolva Holding SA: Update about earn-out from Danstar
Evolva Holding SA: Update about earn-out from Danstar
Lonza Delivers Strong H1 2025 Performance and Upgrades 2025 Full-Year CDMO Sales and Margin Outlook
Lonza Delivers Strong H1 2025 Performance and Upgrades 2025 Full-Year CDMO Sales and Margin Outlook
Lonza Delivers Strong H1 2025 Performance and Upgrades 2025 Full-Year CDMO Sales and Margin Outlook
Change in Siegfried's Executive Committee
Change in Siegfried's Executive Committee
Change in Siegfried's Executive Committee
Evolva Holding SA invites to an Extraordinary General Meeting 2025 to change name to EvoNext Holdings SA
Evolva Holding SA invites to an Extraordinary General Meeting 2025 to change name to EvoNext Holdings SA
Evolva Holding SA invites to an Extraordinary General Meeting 2025 to change name to EvoNext Holdings SA
Annual General Shareholders’ Meeting 2025: Sonova shareholders approve all Board of Directors motions
Annual General Shareholders’ Meeting 2025: Sonova shareholders approve all Board of Directors motions
Annual General Shareholders’ Meeting 2025: Sonova shareholders approve all Board of Directors motions
Edison issues report on BB Biotech (BION)
Edison issues report on BB Biotech (BION)
Edison issues report on BB Biotech (BION)
Evolva Holding SA Takes Note of GZO Shareholder Communities’ Announcementv
Evolva Holding SA Takes Note of GZO Shareholder Communities’ Announcementv
Evolva Holding SA Takes Note of GZO Shareholder Communities’ Announcementv
Lonza Publishes 2024 Comparative Financials Under One Lonza Organizational Structure
Lonza Publishes 2024 Comparative Financials Under One Lonza Organizational Structure
Lonza Publishes 2024 Comparative Financials Under One Lonza Organizational Structure
Evolva Holding SA announces offer to acquire GZO AG and launch a regional healthcare platform
Evolva Holding SA announces offer to acquire GZO AG and launch a regional healthcare platform
Evolva Holding SA announces offer to acquire GZO AG and launch a regional healthcare platform
Siegfried expands production capacity for ophthalmic drugs in El Masnou
Siegfried expands production capacity for ophthalmic drugs in El Masnou
Siegfried expands production capacity for ophthalmic drugs in El Masnou
Lonza Appoints Andreas Bohrer as Chief Legal & Corporate Affairs Officer
Lonza Appoints Andreas Bohrer as Chief Legal & Corporate Affairs Officer
Lonza Appoints Andreas Bohrer as Chief Legal & Corporate Affairs Officer
Sonova publishes Annual Report 2024/25
Sonova publishes Annual Report 2024/25
Sonova publishes Annual Report 2024/25
Lonza Announces Results of the 2025 Annual General Meeting – All Motions Proposed by Board of Directors Approved
Lonza Announces Results of the 2025 Annual General Meeting – All Motions Proposed by Board of Directors Approved
Lonza Announces Results of the 2025 Annual General Meeting – All Motions Proposed by Board of Directors Approved
Financial year 2024/25: Sonova achieves market share gains across all businesses and announces upcoming CEO transition
Financial year 2024/25: Sonova achieves market share gains across all businesses and announces upcoming CEO transition
Financial year 2024/25: Sonova achieves market share gains across all businesses and announces upcoming CEO transition
Lonza Q1 2025 Qualitative Update: Strong Performance Across All Businesses in Line with Expectations for Full-Year 2025
Lonza Q1 2025 Qualitative Update: Strong Performance Across All Businesses in Line with Expectations for Full-Year 2025
Lonza Q1 2025 Qualitative Update: Strong Performance Across All Businesses in Line with Expectations for Full-Year 2025
EQS-Adhoc: BB Biotech AG publishes its interim report
EQS-Adhoc: BB Biotech AG publishes its interim report
EQS-Adhoc: BB Biotech AG publishes its interim report
EQS-News: BB Biotech Q1 2025: Sharpened portfolio focus amid continued market volatility
EQS-News: BB Biotech Q1 2025: Sharpened portfolio focus amid continued market volatility
EQS-News: BB Biotech Q1 2025: Sharpened portfolio focus amid continued market volatility
Sonova concludes 2022-25 share buyback
Sonova concludes 2022-25 share buyback
Sonova concludes 2022-25 share buyback
Siegfried shareholders approve all proposals at Annual General Meeting 2025
Siegfried shareholders approve all proposals at Annual General Meeting 2025
Siegfried shareholders approve all proposals at Annual General Meeting 2025
Lonza Publishes Invitation to the 2025 Annual General Meeting and 2024 Annual and Sustainability Reports
Lonza Publishes Invitation to the 2025 Annual General Meeting and 2024 Annual and Sustainability Reports
Lonza Publishes Invitation to the 2025 Annual General Meeting and 2024 Annual and Sustainability Reports
Lonza Implements its Simplified and Streamlined Operating Model
Lonza Implements its Simplified and Streamlined Operating Model
Lonza Implements its Simplified and Streamlined Operating Model
Lonza Completes its Share Buyback Program
Lonza Completes its Share Buyback Program
Lonza Completes its Share Buyback Program
Evolva Holding SA shareholders elect Clearway representatives to the Board of Directors
Evolva Holding SA shareholders elect Clearway representatives to the Board of Directors
Evolva Holding SA shareholders elect Clearway representatives to the Board of Directors